Ligand Pharmaceuticals Incorporated reaffirmed revenue guidance for the year 2022. For the year, the company expected royalties of $55 million to $60 million, Captisol sales of $40 million to $50 million and contract revenue of $52 million to $62 million. These revenue components result in total revenue of $147 million to $172 million for the combined business.

Ligand expects that $35 million to $45 million of revenue will be attributable to OmniAb, principally in the contract revenue line.